Ref. # | Authors | Number of patients | Type of treatment | Median follow-up | Toxicity |
---|---|---|---|---|---|
[11] | Scorsetti et al. | 50 | SIB, 40.5Gy to whole breast and 48Gy to tumor bed | 12Â months | Skin: Max G3 (1 case) No other toxicity |
[12] | De Rose et al. | 144 | SIB, 40.5Gy to whole breast and 48Gy to tumor bed | 37Â months | Skin max G3 (1 case) Lung: max G1 (36 cases) No other toxicity |
[13] | Riou et al. | 9 | APBI, 40Â Gy in 4Gy fractions twice a day over 5Â days. | 26Â months | Acute: Max G1 Late: Max G1 (inclusive of skin, pneumonitis,pain, oedema) |
[14] | Kim et al. | 31 | VMAT with nodal involvement (internal mammary chain) | 25.2Â months | Late max G2 No cardiac toxicity |
[15] | Lauche et al. | HT: 31 VMAT: 42 | SIB. Tumor bed: 63.2-63.8Gy; whole breast: 52.2Gy; supraclavicular nodes: 50.4Gy; internal mammary chain nodes: 52.2Gy | Not explicitly reported. 3Â months assumption from toxicity assessment statement | Skin: Max G3 (5% of patients, irrespective of technique) Oesophagus: Max G2 (35-40%) No lung toxicity |
[16] | Fiorentino et al. | 16 patients | SIB for synchrounous bilateral breast. 50Gy in 25 fractions to the whole breast, 60Gy to the tumor bed. | 24Â months | No G3 of any type Max G2 acute or late skin toxicity Max G1 acute dysphagia. |